Adstiladrin: Uses, Dosage, Side Effects & Warnings - Drugs.com
Dec 9, 2024 · Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer. Includes …
Bladder Cancer Treatment Options
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive …
Clinical overview Indication: ADSTILADRIN® (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk …
A Plain Language Summary of Nadofaragene Firadenovec Use for Bladder …
Nov 26, 2025 · It just uses the bladder cancer cells as a temporary factory to produce interferon where it's locally needed to treat those and target those cancer cells. So, nadofaragene firadenovec, which …
FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus ...
Apr 1, 2025 · Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients …
First Bladder Cancer Patient Dosed with Commercially Available ...
Sep 12, 2023 · ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin …
Nov 12, 2025 · Gene therapy works by delivering helpful genetic material directly into the bladder to fight cancer cells and boost the body’s immune response. Three gene therapies (nado-faragene …
Nadofaragene firadenovec-vncg (urinary bladder route)
Aug 1, 2025 · Description Nadofaragene Firadenovec-vncg is used to treat patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with a …
Nadofaragene Firadenovec-vncg - NCI - National Cancer Institute
Nadofaragene firadenovec-vncg is approved to treat: Non-muscle–invasive bladder cancer with carcinoma in situ. It is used in adults whose cancer does not respond to treatment with bacillus …
More about ADSTILADRIN® – Bladder Cancer Advocacy Network
What is ADSTILADRIN? ADSTILADRIN (nadofaragene firadenovec-vncg) was approved in the United States in 2022 and is fully available for appropriate patients as a treatment that may help people live …